BRUSSELS, 10/11/2015

IASIS PHARMA proudly announces its participation in a program of H2020. The program Horizon 2020 is the financing framework of the EU for research and Innovation that will cover the period 2014-2020, with a budget of approximately 80 billion Euros.

The program supports the strategy “Europe 2020” that promotes research and innovation as the cornerstones for intelligent, viable and integrated growth aiming in parallel to the effective management of important social challenges.  IASIS PHARMA is the only Greek pharmaceutical industry who acts as a beneficiary to the research project under the distinct title “ΕΧΑΝDAS” of the Marie Sklodowska Curie Actions (MSCA) programs for the exploitation of aromatic plants’ by-products such as the Chios Mastic.

The program coordinator is Assistant Prof. N. Aligiannis, Department of  Pharmacognosy & Chemistry of Natural Products, Faculty of Pharmacy University of Athens (Head, Prof. Skaltsounis). Participants of the program are academic institutions from different countries, such as “Universite Paris Descartes” (France), Institute of Organic Chemistry with Centre of Phytochemistry (Bulgaria), as well as Tunisian, Morrocan and Algerian academic centers and private companies from Bulgaria, France, Germany and the Chios Mastic Growers Association. The results of the project are expected to be announced in the summer of 2020.